ATE295168T1 - Zusammensetzung von riluzol und alpha-tocopherol - Google Patents

Zusammensetzung von riluzol und alpha-tocopherol

Info

Publication number
ATE295168T1
ATE295168T1 AT99972101T AT99972101T ATE295168T1 AT E295168 T1 ATE295168 T1 AT E295168T1 AT 99972101 T AT99972101 T AT 99972101T AT 99972101 T AT99972101 T AT 99972101T AT E295168 T1 ATE295168 T1 AT E295168T1
Authority
AT
Austria
Prior art keywords
riluzole
tocopherol
alpha
composition
combination
Prior art date
Application number
AT99972101T
Other languages
English (en)
Inventor
Michel Dib
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE295168T1 publication Critical patent/ATE295168T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • External Artificial Organs (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
AT99972101T 1998-11-13 1999-11-09 Zusammensetzung von riluzol und alpha-tocopherol ATE295168T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9814250A FR2785808B1 (fr) 1998-11-13 1998-11-13 Association riluzole et alpha-tocopherol
PCT/FR1999/002753 WO2000028992A1 (fr) 1998-11-13 1999-11-09 Association riluzole et alpha-tocopherol

Publications (1)

Publication Number Publication Date
ATE295168T1 true ATE295168T1 (de) 2005-05-15

Family

ID=9532674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972101T ATE295168T1 (de) 1998-11-13 1999-11-09 Zusammensetzung von riluzol und alpha-tocopherol

Country Status (23)

Country Link
US (2) US6642262B2 (de)
EP (1) EP1128829B1 (de)
JP (1) JP4693241B2 (de)
KR (1) KR100641472B1 (de)
CN (1) CN1177587C (de)
AT (1) ATE295168T1 (de)
AU (1) AU776242B2 (de)
BR (1) BR9915292A (de)
CA (1) CA2350671C (de)
CZ (1) CZ298808B6 (de)
DE (1) DE69925301T2 (de)
DK (1) DK1128829T3 (de)
EA (1) EA003671B1 (de)
ES (1) ES2239858T3 (de)
FR (1) FR2785808B1 (de)
HK (1) HK1041220B (de)
HU (1) HU226067B1 (de)
IL (1) IL142708A0 (de)
NO (1) NO328349B1 (de)
PT (1) PT1128829E (de)
TR (1) TR200101346T2 (de)
WO (1) WO2000028992A1 (de)
ZA (1) ZA200103810B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
JPWO2007046347A1 (ja) * 2005-10-18 2009-04-23 小野薬品工業株式会社 筋萎縮性側索硬化症患者の運動神経保護用医薬
US20070099156A1 (en) * 2005-10-28 2007-05-03 Jeff Wagner Self-etching dental primer compositions and methods and systems utilizing such compositions
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2014145776A2 (en) * 2013-03-15 2014-09-18 Baylor College Of Medicine Msp and its receptors in the therapy of amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5843641A (en) * 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
US6380252B1 (en) * 1996-07-05 2002-04-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
JP3889844B2 (ja) * 1997-02-10 2007-03-07 龍兒 梶 筋萎縮性側索硬化症治療剤
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique

Also Published As

Publication number Publication date
IL142708A0 (en) 2002-03-10
EP1128829B1 (de) 2005-05-11
PT1128829E (pt) 2005-07-29
US20030125363A1 (en) 2003-07-03
ES2239858T3 (es) 2005-10-01
CA2350671A1 (fr) 2000-05-25
WO2000028992A1 (fr) 2000-05-25
CZ20011561A3 (cs) 2001-08-15
NO20012308L (no) 2001-05-10
EA003671B1 (ru) 2003-08-28
EP1128829A1 (de) 2001-09-05
KR20010080407A (ko) 2001-08-22
CZ298808B6 (cs) 2008-02-06
US6642262B2 (en) 2003-11-04
BR9915292A (pt) 2001-08-07
AU776242B2 (en) 2004-09-02
HU226067B1 (en) 2008-04-28
FR2785808A1 (fr) 2000-05-19
AU1165500A (en) 2000-06-05
NO20012308D0 (no) 2001-05-10
HUP0105301A2 (hu) 2002-05-29
KR100641472B1 (ko) 2006-10-31
HK1041220B (zh) 2005-07-22
CN1177587C (zh) 2004-12-01
JP4693241B2 (ja) 2011-06-01
CA2350671C (fr) 2010-05-04
FR2785808B1 (fr) 2002-12-06
CN1326348A (zh) 2001-12-12
EA200100530A1 (ru) 2001-10-22
NO328349B1 (no) 2010-02-01
TR200101346T2 (tr) 2002-05-21
ZA200103810B (en) 2002-08-12
DK1128829T3 (da) 2005-08-29
HK1041220A1 (en) 2002-07-05
US20020019426A1 (en) 2002-02-14
DE69925301D1 (de) 2005-06-16
DE69925301T2 (de) 2006-01-26
JP2002529506A (ja) 2002-09-10
HUP0105301A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
DK1214936T3 (da) Anvendelse af thiazolidin- eller pyrrolidinderivater af aminosyrer som antihyperglykæmiske midler
DK0797439T3 (da) Anvendelse af pramipexol som et neurobeskyttende middel
EA199800667A1 (ru) Новые фенантридины
NO912630L (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler som antiarteriosklerotiske midler
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
ES2127397T3 (es) Sulfonamidas y sus derivados que modulan la actividad de la endotelina.
BR0215405A (pt) Composições e processos de uso de collajolie
ATE196761T1 (de) Inhibitoren retroviraler proteasen
BR0317715A (pt) Composições e processos de uso de collajolie
NO307336B1 (no) 2-[(Dihydro)pyrazolyl-3'-oksylmetylen]anilider, anvendelse derav, samt middel inneholdende forbindelsen og mellomprodukter for fremstilling av forbindelsen
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
ITRM940150A0 (it) Procedimento per il trattamento di acque di scarico fortemente colorate.
DK0572166T3 (da) Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
TR199701654T1 (xx) 4-Fenilaminotiyazol t�revleri.
DE60330180D1 (de) Kosmetische zusammensetzung enthaltend ein siegesbeckia extrakt und ein lipopeptid
DK1119359T3 (da) 2-methyl-thieno-benzodiazepinformulering
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69925301D1 (de) Zusammensetzung von riluzol und alpha-tocopherol
ATE211719T1 (de) Korrosionsinhibitoren enthaltender injektionszement
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
SE9704770D0 (sv) New use
IL127930A0 (en) Verapamil as a medicament for the treatment of angina
FR2778102B1 (fr) Utilisation d'oligomeres procyanidoliques (opc) ou d'anthocyanosides a titre d'agents anti-urease
SE9303060D0 (sv) Löstagbar stoppanordning
ECSP972052A (es) Quinoxalinadionas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1128829

Country of ref document: EP